A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Sponsor
Bristol-Myers Squibb
Study ID
NCT06104644
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Deucravacitinib — DRUG
    Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics

Study Details

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

Key Dates

Start date
Apr 13, 2023
Status verified
Nov 2025
Primary completion
Aug 18, 2025
Completion
May 31, 2030

Study Design

Enrollment
550 participants (estimated)

Arms

  • Arm: Moderate-to-severe plaque psoriasis

Primary Outcome Measure

Proportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit [ Time Frame: Approximately 24 weeks after treatment initiation (data to be collected at visit nearest to this timepoint) ]

Related Studies